PYC Therapeutics (PYC) Stock Price, News & Analysis

Company Overview

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. The company's preclinical development programs include VP-001, a drug program for retinitis pigmentosa type 11; PYC-001, a drug program for the treatment of autosomal dominant optic atrophy; and PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: A$611.26 million
• P/E Ratio: N/A
• Dividend Yield: 9.46%
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:PYC
• CIK: N/A
• Web: pyctx.com
• Phone: 61 8 6151 0992
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$37.73 million
• Net Margins: -171.02%
• Pretax Margin: N/A
• Return on Equity: -68.34%
• Return on Assets: -37.83%

Debt

• Debt-to-Equity Ratio: 1.38
• Current Ratio: 9.40
• Quick Ratio: 8.93

Sales & Book Value

• Annual Sales: A$22.06 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.02 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,670,000,000
• Free Float: N/A
• Market Cap: A$611.26 million
• Optionable: Not Optionable
• Beta: 0.71